Organigram Holdings Inc. (TSE:OGI - Free Report) - Stock analysts at Atb Cap Markets issued their Q4 2025 earnings per share (EPS) estimates for Organigram in a research note issued on Wednesday, December 18th. Atb Cap Markets analyst F. Gomes expects that the company will earn ($0.01) per share for the quarter. The consensus estimate for Organigram's current full-year earnings is $0.16 per share.
A number of other analysts also recently weighed in on OGI. ATB Capital cut their price target on shares of Organigram from C$5.25 to C$3.50 in a research report on Tuesday. Canaccord Genuity Group dropped their price objective on Organigram from C$3.60 to C$3.15 and set a "speculative buy" rating on the stock in a research note on Monday, December 9th.
Get Our Latest Stock Report on OGI
TSE OGI opened at C$2.09 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 2.62 and a current ratio of 6.95. Organigram has a 52 week low of C$1.61 and a 52 week high of C$3.95. The stock has a market capitalization of C$226.91 million, a P/E ratio of -0.83, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13. The stock has a fifty day moving average of C$2.26 and a 200-day moving average of C$2.30.
In other Organigram news, Senior Officer Paolo De Luca sold 12,014 shares of the stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of C$2.52, for a total value of C$30,275.28. Corporate insiders own 31.32% of the company's stock.
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.